Fig. 5From: Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinibTMB was associated with the clinical response to Osimertinib. A Forest plot of hazard ratio (HR) and p value for ultivariate analyses of different TMB-H cut-off value. B Comparison of PFS between patients of TMB-H (≥ 6 mutations/MB) and patients of TMB-L (< 6 mutations/MB)Back to article page